Renate Strehlau to Anti-HIV Agents
This is a "connection" page, showing publications Renate Strehlau has written about Anti-HIV Agents.
Connection Strength
3,895
-
HIV diagnostic challenges in breast-fed infants of mothers on antiretroviral therapy. AIDS. 2019 09 01; 33(11):1751-1756.
Score: 0,352
-
Substituting Abacavir for Stavudine in Children Who Are Virally Suppressed Without Lipodystrophy: Randomized Clinical Trial in Johannesburg, South Africa. J Pediatric Infect Dis Soc. 2018 Aug 17; 7(3):e70-e77.
Score: 0,327
-
Neurodevelopmental assessment of HIV-exposed uninfected and early-treated HIV-infected children: study protocol. BMC Res Notes. 2018 Apr 06; 11(1):235.
Score: 0,319
-
HIV-associated neurodevelopmental delay: prevalence, predictors and persistence in relation to antiretroviral therapy initiation and viral suppression. Child Care Health Dev. 2016 11; 42(6):881-889.
Score: 0,285
-
Developmental status of preschool children receiving cART: a descriptive cohort study. Child Care Health Dev. 2016 May; 42(3):410-4.
Score: 0,275
-
PRINCE-1: safety and efficacy of atazanavir powder and ritonavir liquid in HIV-1-infected antiretroviral-naïve and -experienced infants and children aged =3 months to <6 years. J Int AIDS Soc. 2015; 18:19467.
Score: 0,262
-
Lipid profiles in young HIV-infected children initiating and changing antiretroviral therapy. J Acquir Immune Defic Syndr. 2012 Aug 01; 60(4):369-76.
Score: 0,215
-
Absence seizures associated with efavirenz initiation. Pediatr Infect Dis J. 2011 Nov; 30(11):1001-3.
Score: 0,204
-
Pharmacokinetics, safety and efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in children with HIV aged from 2 years and weighing at least 14 kg. J Int AIDS Soc. 2025 Feb; 28(2):e26414.
Score: 0,128
-
Pharmacokinetics and safety of coformulated bictegravir, emtricitabine, and tenofovir alafenamide in children aged 2 years and older with virologically suppressed HIV: a phase 2/3, open-label, single-arm study. Lancet HIV. 2024 May; 11(5):e300-e308.
Score: 0,121
-
Healthy dynamics of CD4 T cells may drive HIV resurgence in perinatally-infected infants on antiretroviral therapy. PLoS Pathog. 2022 08; 18(8):e1010751.
Score: 0,108
-
Predictors of Cell-Associated Human Immunodeficiency Virus (HIV)-1 DNA Over 1 Year in Very Early Treated Infants. Clin Infect Dis. 2022 03 23; 74(6):1047-1054.
Score: 0,105
-
Switch to Efavirenz Attenuates Lipoatrophy in Girls With Perinatal HIV. J Pediatr Gastroenterol Nutr. 2021 01 01; 72(1):e15-e20.
Score: 0,096
-
Quantifying the Dynamics of HIV Decline in Perinatally Infected Neonates on Antiretroviral Therapy. J Acquir Immune Defic Syndr. 2020 10 01; 85(2):209-218.
Score: 0,095
-
Deficits in Bone Architecture and Strength in Children Living With HIV on Antiretroviral Therapy. J Acquir Immune Defic Syndr. 2020 05 01; 84(1):101-106.
Score: 0,092
-
Negative Diagnostic PCR Tests in School-Aged, HIV-Infected Children on Antiretroviral Therapy Since Early Life in Johannesburg, South Africa. J Acquir Immune Defic Syndr. 2020 04 01; 83(4):381-389.
Score: 0,092
-
Distinct epigenetic profiles in children with perinatally-acquired HIV on antiretroviral therapy. Sci Rep. 2019 07 19; 9(1):10495.
Score: 0,087
-
Mitochondrial Impairment in Well-Suppressed Children with Perinatal HIV-Infection on Antiretroviral Therapy. AIDS Res Hum Retroviruses. 2020 01; 36(1):27-38.
Score: 0,087
-
Patterns of Growth, Body Composition, and Lipid Profiles in a South African Cohort of Human Immunodeficiency Virus-Infected and Uninfected Children: A Cross-Sectional Study. J Pediatric Infect Dis Soc. 2018 May 15; 7(2):143-150.
Score: 0,080
-
Age at antiretroviral therapy initiation and cell-associated HIV-1 DNA levels in HIV-1-infected children. PLoS One. 2018; 13(4):e0195514.
Score: 0,080
-
Switching to Efavirenz Versus Remaining on Ritonavir-boosted Lopinavir in Human Immunodeficiency Virus-infected Children Exposed to Nevirapine: Long-term Outcomes of a Randomized Trial. Clin Infect Dis. 2017 Aug 01; 65(3):477-485.
Score: 0,076
-
Case report: Severe central nervous system manifestations associated with aberrant efavirenz metabolism in children: the role of CYP2B6 genetic variation. BMC Infect Dis. 2016 Feb 02; 16:56.
Score: 0,069
-
Plasma lopinavir concentrations predict virological failure in a cohort of South African children initiating a protease-inhibitor-based regimen. Antivir Ther. 2014; 19(4):399-406.
Score: 0,060
-
Sex differences in responses to antiretroviral treatment in South African HIV-infected children on ritonavir-boosted lopinavir- and nevirapine-based treatment. BMC Pediatr. 2014 Feb 12; 14:39.
Score: 0,060
-
Poor early virologic performance and durability of abacavir-based first-line regimens for HIV-infected children. Pediatr Infect Dis J. 2013 Aug; 32(8):851-5.
Score: 0,058
-
Metabolic abnormalities and body composition of HIV-infected children on Lopinavir or Nevirapine-based antiretroviral therapy. Arch Dis Child. 2013 Apr; 98(4):258-64.
Score: 0,055
-
Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: long-term follow-up of a randomised, open-label trial. Lancet Infect Dis. 2012 Jul; 12(7):521-30.
Score: 0,052
-
Growth Trajectories Over the First Year of Life Among Early-Treated Infants with Human Immunodeficiency Virus and Infants Who are Human Immunodeficiency Virus-Exposed Uninfected. J Pediatr. 2024 Jul; 270:114018.
Score: 0,030
-
Abacavir Exposure in Children Cotreated for Tuberculosis with Rifampin and Superboosted Lopinavir-Ritonavir. Antimicrob Agents Chemother. 2020 04 21; 64(5).
Score: 0,023